These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 4332693)

  • 1. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.
    Ungerstedt U
    Acta Physiol Scand Suppl; 1971; 367():69-93. PubMed ID: 4332693
    [No Abstract]   [Full Text] [Related]  

  • 2. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour.
    Ungerstedt U
    Acta Physiol Scand Suppl; 1971; 367():49-68. PubMed ID: 4332692
    [No Abstract]   [Full Text] [Related]  

  • 3. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system.
    Ungerstedt U
    Acta Physiol Scand Suppl; 1971; 367():95-122. PubMed ID: 4332694
    [No Abstract]   [Full Text] [Related]  

  • 4. Actions of levodopa and dopamine in the central nervous system.
    Sourkes TL
    JAMA; 1971 Dec; 218(13):1909-11. PubMed ID: 4398939
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased acoplasmic transport of H3-dopamine in nigro-neostriatal neurons after reserpine.
    Fibiger HC; McGeer EG
    Life Sci; 1973 Dec; 13(11):1565-71. PubMed ID: 4588712
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
    Mendez JS; Finn BW
    J Neurosurg; 1975 Feb; 42(2):166-73. PubMed ID: 234524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central actions of dopa and dopamine.
    Sourkes TL
    Rev Can Biol; 1972; 31():Suppl:153-68. PubMed ID: 4403289
    [No Abstract]   [Full Text] [Related]  

  • 8. Denervation-like postsynaptic supersensitivity to dopamine agonists induced by microinjection of colchicine into the substantia nigra pars compacta.
    Kamata K; Kameyama T; Okuyama S; Hashimoto S; Aihara H
    Brain Res; 1986 Mar; 367(1-2):1-7. PubMed ID: 3008917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD; Creese I
    Adv Neurol; 1975; 9():81-92. PubMed ID: 1170717
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
    Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK
    Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural sequelae of dopaminergic degeneration: postsynaptic supersensitivity?
    Creese I; Iversen SD
    Psychopharmacol Bull; 1975 Oct; 11(4):12-3. PubMed ID: 1197588
    [No Abstract]   [Full Text] [Related]  

  • 12. A model for the quantitative study of central dopaminergic and serotoninergic activity.
    Bieger D; Larochelle L; Hornykiewicz O
    Eur J Pharmacol; 1972 Apr; 18(1):128-36. PubMed ID: 4555562
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-induced rotation in rats without lesions: behavioral and neurochemical indices of a normal asymmetry in nigro-striatal function.
    Jerussi TP; Glick SD
    Psychopharmacology (Berl); 1976 Jun; 47(3):249-60. PubMed ID: 823560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of LSD and 2-bromo LSD on the striatal DOPA accumulation after decarboxylase inhibition in rats.
    Persson SA
    Eur J Pharmacol; 1977 May; 43(1):73-83. PubMed ID: 16756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Costall B; Naylor RJ; Pycock C
    Eur J Pharmacol; 1976 Feb; 35(2):276-83. PubMed ID: 942921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones.
    Bunney BS; Aghajanian GK; Roth RH
    Nat New Biol; 1973 Sep; 245(143):123-5. PubMed ID: 4518113
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of different doses of apomorphine on the glutamate decarboxylase activity of the substantia nigra and the medial basal hypothalamus].
    Giammona G; Pattí F; Sambataro V; Reggio A; Rampello L; Di Giorgio RM; Maccagnano C; Condorelli DF; Nicoletti F
    Boll Soc Ital Biol Sper; 1981 Oct; 57(20):2074-9. PubMed ID: 7317201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent changes in the sensitivity of dopamine neurons to low doses of apomorphine following amphetamine infusion.
    Lee TH; Ellinwood EH
    Brain Res; 1989 Mar; 483(1):17-29. PubMed ID: 2495842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.